Bedaquiline for multidrug-resistant TB in paediatric patients

BACKGROUND: TMC207-C211 (NCT02354014) is a Phase 2, open-label, multicentre, single-arm study to evaluate pharmacokinetics, safety/tolerability, antimycobacterial activity and dose selection of bedaquiline (BDQ) in children (birth to <18 years) with multidrug-resistant-TB (MDR-TB). METHODS: Patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Moodliar, R., Aksenova, V., Frias, M. V. G., van de Logt, J., Rossenu, S., Birmingham, E., Zhuo, S., Mao, G., Lounis, N., Kambili, C., Bakare, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union Against Tuberculosis and Lung Disease 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412106/
https://www.ncbi.nlm.nih.gov/pubmed/34802493
http://dx.doi.org/10.5588/ijtld.21.0022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412106/
https://www.ncbi.nlm.nih.gov/pubmed/34802493
http://dx.doi.org/10.5588/ijtld.21.0022

Ejemplares similares